At a glance
- Pasireotide is an FDA-approved drug, marketed as Signifor (first approval: December 14, 2012).
- PubMed lists 844 publications mentioning it, including 54 randomized controlled trials and 56 animal-only studies.
- ClinicalTrials.gov lists 87 registered studies testing it (8 active).
- FDA's adverse event system (FAERS) holds 2,698 reports mentioning it; 2,028 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA200677 | SIGNIFOR | Approved, marketed | December 14, 2012 | RECORDATI RARE |
| NDA203255 | SIGNIFOR LAR KIT | Approved, marketed | December 15, 2014 | RECORDATI RARE |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Lanreotide for the prevention of postoperative pancreatic fistula (S2408): study protocol for a multicenter randomized controlled trial.
- Personalised acromegaly treatment: implementing precision medicine in the Gulf States.
- Should radiotherapy be repositioned in the contemporary management of acromegaly?
- New and emerging pharmacological treatment options for acromegaly: a 2026 update.
- Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.
- Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.
- Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.
- Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation.
- Management and safety of somatostatin receptor ligands and pegvisomant in pregnant women with acromegaly: a narrative review of the literature.
- Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 87
- Active
- 8
- With posted results
- 40
Conditions studied
Show 40 more studies
All 87 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 2,698
- Serious
- 2,028
- With death outcome
- 185
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.